Therapeutic microRNA Delivery Strategies with Special Emphasis on Cancer Therapy and Tumorigenesis: Current Trends and Future Challenges

被引：17
作者：
Chakraborty, Chiranjib [1 ,2 ,3 ]
Wen, Zhi-Hong [2 ,3 ]
Agoramoorthy, Govindasamy [4 ]
Lin, Chan-Shing [2 ,3 ]
机构：
[1] Galgotias Univ, Dept Bioinformat, Sch Comp & Informat Sci, Greater Noida, Uttar Pradesh, India
[2] Natl Sun Yat Sen Univ, Coll Marine Sci, Dept Marine Biotechnol & Resources, Kaohisung, Taiwan
[3] Natl Sun Yat Sen Univ, Asia Pacific Ocean Res Ctr, Div Marine Biotechnol, Kaohisung, Taiwan
[4] Tajen Univ, Coll Pharm & Hlth Care, Pingtung 907, Taiwan
来源：
CURRENT DRUG METABOLISM | 2016年 / 17卷 / 05期
关键词：
Biopharmaceutical industry; cancer therapy; miRNA delivery; therapeutic microRNA; tumorigenesis; SMALL INTERFERING RNAS; NUCLEIC-ACID; IN-VIVO; REPLACEMENT THERAPY; PANCREATIC-CANCER; TARGETED DELIVERY; CELL-PROLIFERATION; INSULIN-RESISTANCE; MEDIATED DELIVERY; PROSTATE-CANCER;
D O I：
10.2174/1389200217666160126142408
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Background: Over the decade, miRNAs are the most important molecules for the biopharmaceutical industry due to their relation with several human diseases. Presently, the phase-II clinical trial has been initiated for the first miRNA-based therapeutics ("Miravirsen") to treat HCV infection. It has been expected that many more miRNA-based therapeutics will enter the clinical trials. Therefore, it is important to develop different kinds of novel delivery systems with better efficacy and more efficiency, but fewer side effects. Methods: We have undertaken a structured search of bibliographic databases for peer-reviewed research literature to solve our review question. Literature survey was performed widely to write this review article. Results: In this review, we have discussed the various types of miRNA delivery systems such as viral vectors, lipid-based systems, nanocarriers, and LNA-customized DNA delivery without any delivery-mediated agent. Current status, technical support, and the future challenges for miRNA-based delivery are also discussed. Conclusion: Recent development and understanding of miRNA had shown the therapeutic potentiality of miRNA.
引用
收藏
页码：469 / 477
页数：9
相关论文
共 101 条
[1]  
Alexander A., 2012, AM J DRUG DISCOVERY, V2, P143, DOI [DOI 10.3923/AJDD.2012.143.183, 10.3923/ajdd.2012.143.183]
[2]   Nanoparticle-based therapy in an in vivo microRNA-155 (miR-155)-dependent mouse model of lymphoma [J].
Babar, Imran A. ;
Cheng, Christopher J. ;
Booth, Carmen J. ;
Liang, Xianping ;
Weidhaas, Joanne B. ;
Saltzman, W. Mark ;
Slack, Frank J. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2012, 109 (26) :E1695-E1704
[3]  
Bader Andreas G., 2012, Frontiers in Genetics, V3, P120, DOI 10.3389/fgene.2012.00120
[4]   The Promise of MicroRNA Replacement Therapy [J].
Bader, Andreas G. ;
Brown, David ;
Winkler, Matthew .
CANCER RESEARCH, 2010, 70 (18) :7027-7030
[5]   INTERFERING NANOPARTICLES FOR SILENCING MICRORNAS [J].
Baigude, Huricha ;
Rana, Tariq M. .
NANOMEDICINE: INFECTIOUS DISEASES, IMMUNOTHERAPY, DIAGNOSTICS, ANTIFIBROTICS, TOXICOLOGY AND GENE MEDICINE, 2012, 509 :339-353
[6]   MicroRNAs: Genomics, biogenesis, mechanism, and function (Reprinted from Cell, vol 116, pg 281-297, 2004) [J].
Bartel, David P. .
CELL, 2007, 131 (04) :11-29
[7]   Therapeutic inhibition of the miR-34 family attenuates pathological cardiac remodeling and improves heart function [J].
Bernardo, Bianca C. ;
Gao, Xiao-Ming ;
Winbanks, Catherine E. ;
Boey, Esther J. H. ;
Tham, Yow Keat ;
Kiriazis, Helen ;
Gregorevic, Paul ;
Obad, Susanna ;
Kauppinen, Sakari ;
Du, Xiao-Jun ;
Lin, Ruby C. Y. ;
McMullen, Julie R. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2012, 109 (43) :17615-17620
[8]   The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities [J].
Bonci, Desiree ;
Coppola, Valeria ;
Musumeci, Maria ;
Addario, Antonio ;
Giuffrida, Raffaella ;
Memeo, Lorenzo ;
D'Urso, Leonardo ;
Pagliuca, Alfredo ;
Biffoni, Mauro ;
Labbaye, Catherine ;
Bartucci, Monica ;
Muto, Giovanni ;
Peschle, Cesare ;
De Maria, Ruggero .
NATURE MEDICINE, 2008, 14 (11) :1271-1277
[9]   Getting pharmaceutical R&D back on target [J].
Bunnage, Mark E. .
NATURE CHEMICAL BIOLOGY, 2011, 7 (06) :335-339
[10]   Protamine sulfate-nanodiamond hybrid nanoparticles as a vector for MiR-203 restoration in esophageal carcinoma cells [J].
Cao, Minjun ;
Deng, Xiongwei ;
Su, Shishuai ;
Zhang, Fang ;
Xiao, Xiangqian ;
Hu, Qin ;
Fu, Yongwei ;
Yang, Burton B. ;
Wu, Yan ;
Sheng, Wang ;
Zeng, Yi .
NANOSCALE, 2013, 5 (24) :12120-12125
12345678910